Article
Muscleblind-like 1 (Mbnl1) promotes insulin receptor exon 11 inclusion via binding to a downstream evolutionarily conserved intronic enhancer.
Medical Research Service, Veterans Affairs San Diego Healthcare System, San Diego, California, USA.
Journal of Biological Chemistry (impact factor:
4.77).
08/2010;
285(33):25426-37.
DOI:10.1074/jbc.M109.095224
pp.25426-37
Source: PubMed
-
Citations (0)
- Cited In (7)
-
Article: Alternative splicing produces structural and functional changes in CUGBP2.
[show abstract] [hide abstract]
ABSTRACT: CELF/Bruno-like proteins play multiple roles, including the regulation of alternative splicing and translation. These RNA-binding proteins contain two RNA recognition motif (RRM) domains at the N-terminus and another RRM at the C-terminus. CUGBP2 is a member of this family of proteins that possesses several alternatively spliced exons. The present study investigated the expression of exon 14, which is an alternatively spliced exon and encodes the first half of the third RRM of CUGBP2. The ratio of exon 14 skipping product (R3δ) to its inclusion was reduced in neuronal cells induced from P19 cells and in the brain. Although full length CUGBP2 and the CUGBP2 R3δ isoforms showed a similar effect on the inclusion of the smooth muscle (SM) exon of the ACTN1 gene, these isoforms showed an opposite effect on the skipping of exon 11 in the insulin receptor gene. In addition, examination of structural changes in these isoforms by molecular dynamics simulation and NMR spectrometry suggested that the third RRM of R3δ isoform was flexible and did not form an RRM structure. Our results suggest that CUGBP2 regulates the splicing of ACTN1 and insulin receptor by different mechanisms. Alternative splicing of CUGBP2 exon 14 contributes to the regulation of the splicing of the insulin receptor. The present findings specifically show how alternative splicing events that result in three-dimensional structural changes in CUGBP2 can lead to changes in its biological activity.BMC Biochemistry 03/2012; 13:6. · 1.99 Impact Factor -
Article: The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers.
[show abstract] [hide abstract]
ABSTRACT: An increasing body of evidence connects alterations in the process of alternative splicing with cancer development and progression. However, a direct role of splicing factors as drivers of cancer development is mostly unknown. We analyzed the gene copy number of several splicing factors in colon and lung tumors and found that the gene encoding for the splicing factor SRSF6 is amplified and overexpressed in these cancers. Moreover, overexpression of SRSF6 in immortal lung epithelial cells enhanced proliferation, protected them from chemotherapy-induced cell death and converted them to be tumorigenic in mice. In contrast, knockdown of SRSF6 in lung and colon cancer cell lines inhibited their tumorigenic abilities. SRSF6 up- or down regulation altered the splicing of several tumor suppressors and oncogenes to generate the oncogenic isoforms and reduce the tumor suppressive isoforms. Our data suggests that the splicing factor SRSF6 is an oncoprotein which regulates proliferation and survival of lung and colon cancer cells. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.The Journal of Pathology 11/2012; · 6.32 Impact Factor -
Chapter: hnRNP and hnRNP‑Like Proteins in Splicing Control: Molecular Mechanisms and Implication in Human Pathologies
[show abstract] [hide abstract]
ABSTRACT: The heterogeneous nuclear ribonucleoprotein (hnRNP) family includes a diverse group of RNA binding proteins to which we are affiliating here other structurally and functionally related proteins (e.g., Nova, Sam68, ESRP, Fox, TDP‑43, Hu, CUG‑BP, MBNL and TIA proteins). These hnRNP and hnRNP‑like proteins make important contributions to protein diversity and activity by modulating the alternative splicing of a large repertoire of pre‑mRNAs. They achieve this function through a variety of molecular strategies ranging from directly preventing the recognition of splice sites, antagonizing or helping the assembly of positive regulatory complexes, interfering with spliceosome assembly and changing the conformation of pre‑mRNAs. In addition to regulating key splicing events, defects in the expression of these proteins are now being documented for a growing number of human diseases including cancer. hnRNP and hnRNP‑like proteins therefore represent a group of proteins whose roles in the control of splicing pervade all areas of biology and human health.01/2011: pages 1-25;
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
affect insulin receptor splicing
CELF protein CUG-BP1
different disease states
downstream intronic enhancer element
embryonic kidney cells
exon 11 inclusion
exon inclusion
insulin receptor exon 11 inclusion
insulin receptor gene
intron 10
intronic splicing enhancer
Mbnl1 binds
new intronic splicing element
primary transcript
regulatory sequences
relative proportions
ribonucleoprotein immunoprecipitation
RNA affinity chromatography
sequence functions
spliced exon 11